Oxaliplatin, a platinum-based chemotherapeutic agent with a 1, 2-diaminocyclohexane (DACH)
carrier ligand, has shown in vitro and in vivo efficacy against many tumor cell lines, …

Damage to cellular DNA is believed to determine the antiproliferative properties of platinum (Pt)
drugs. This study characterized DNA damage by oxaliplatin, a diaminocyclohexane Pt …

… In these systems, we also found that oxaliplatin can induce DNA-protein cross-links (Woynarowski
JM, Faivre S, Chapman WG, unpublished observations). … Woynarowski JM …

Platinum anticancer drugs, such as cisplatin, are thought to exert their activity by DNA
damage. Oxaliplatin, a clinically active diaminocyclohexane platinum compound, however, …

Elimination of cancer cells by early apoptosis is preferred over other forms of cell growth
inhibition. Apoptosis directly leads to tumor regression and reduces risks of selecting more …

Purpose: This study assessed the cytotoxic effects of the nucleoside analog gemcitabine in
combination with the diaminocyclohexane platinum compound oxaliplatin. Methods: Growth …

The effects of distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole (DAPI) on the
catalytic activity of topoisomerase II from L1210 cells were determined. These compounds …

7-Alkyl, 7-alkyl-10-hydroxy, 7-alkyl-10-methoxy, and 7-alkyl-10,11-methylenedioxy analogs
of camptothecin have been synthesized and evaluated for their ability to trap human DNA …

… ability of “C-labeled HMAF to bind to DNA, although proteins appeared to be more
extensively adducted (Herzig M and Woynarowski JM, unpublished results). HMAF-induced …

Cellular DNA is not a uniform target for DNA-reactive drugs. At the nucleotide level, drugs
recognize and bind short motifs of a few base pairs. The location of drug adducts at the …